Company intelligence
DCN Dx
Diagnostic Product Development for Every Application
About DCN Dx
DCN Dx specializes in the contract development of rapid point of care tests. We offer a variety of services and products that assist our clients in the design and development of user-centric, high performing diagnostic devices. Contract development of rapid immunoassays is at the core of all that we do at DCN Dx. We focus on lateral flow, flow through, and microfuidic formats. Our staff has unparalleled experience in developing assays with tough specifications, regarding high sensitivity, quantification, multiplexing and reader integration. Our ISO 9001:2015 compliant development process allows for close integration of assay and device development pathways, which ensures the best chance of commercial success for the product. As well as developing the assay itself, DCN Dx's integrated engineering team will design, develop and integrate your entire device. The engineers work closely with our scientists to create cassettes and sample handling devices that enhance the performance of your assay and meet all end-user specifications. We deliver the product, not just the parts. DCN Dx also offers a variety of products and services to assist our clients at any stage of development, including: - Custom, private education and training courses in lateral flow technology, during which we teach the details of how to develop and manufacture rapid assays. - Consulting services to assist with any aspect of rapid assay development, manufacturing, regulation and commercialization. - Custom protein-protein, protein-particle, small molecule-protein and small molecule- particle conjugations. - Lateral flow material starter kits, conjugation kits, reagents, cassettes and materials for use during rapid assay development. DCN Dx represents a single source that can help you manage and deliver completely validated assay platforms. CONTACT US: www.dcndx.com info@dcndx.com (760) 804-3886
Verified activity
Signals from DCN Dx
6 published signals
Products & Services
DCN Dx offers a Wellness Regulatory Assessment led by Dan to assess how FDA policy may apply to a product, the likely regulatory path, and whether to contact FDA.
Reported by DCN Dx
Research & Knowledge
DCN Dx hosted an Expert Insights conversation with Blythe Karow and Dan Simpson about product moving from tracking sleep or recovery into reporting a biomarker.
Reported by Emily Friedland
Products & Services
DCN Dx leads the fixed-fee Wellness Regulatory Assessment, which gives teams a short regulatory sprint to get a product-specific view before choosing a regulatory path or going to market.
Reported by Emily Friedland
Presence & Recognition
DCN Dx hosted an RAPS webcast featuring Dan Simpson and Sarah Barchard discussing IVDR and FDA pathways for EU and US market entry.
Reported by DCN Dx
Presence & Recognition
DCN Dx team members Dan Simpson and Scott Robitaille will attend the Regulatory Affairs Professionals Society (RAPS) Convergence meeting in Charlotte from September 15 to 17, 2026, with IVD developers discussing regulatory strategy, clinical research, submission pathways, evidence requirements, study planning, and clinical execution.
Reported by DCN Dx
People
DCN Dx celebrated its 5-year anniversary.
Reported by Emily Friedland